SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
880Approval doesn't seem to be having an AH effect, or hasn't been noticed.Ian@SI-11/29/2012
879Genentech also testing 518 in a phase I combo trial with a pan-Akt inhibitor froscaram(o)uche-10/13/2012
878EXEL - (graphics better on the link) hammerstockblog.com Exelixis - First parIRWIN JAMES FRANKEL-10/4/2012
877(deleted, duplicate post)scaram(o)uche-9/29/2012
876<i>Roche has disclosed that it intends to evaluate the combination of vemuscaram(o)uche-9/29/2012
875>> Not a bad position to be in to be partnered with a company that alreadyscaram(o)uche-9/29/2012
874Sounds good to me. but with the FDA, one can never be certain... SOUTH SAN FRIan@SI-8/29/2012
873This was worth a whole nickle at the close for EXEL... FDA Grants Priority ReviIan@SI-7/30/2012
872siliconinvestor.comtom pope-6/3/2012
871SOUTH SAN FRANCISCO, Calif. (Business Wire) -- Exelixis, Inc. (NASDAQ:EXEL) todIan@SI-6/2/2012
870Too many people at yahoo respond by frothing at the mouth. <i>Fraudsteintom pope-5/8/2012
869"The bear case for EXEL" see: siliconinvestor.com Cheers, Tucktuck-5/8/2012
868Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP CollaboraIRWIN JAMES FRANKEL-5/3/2012
867From YM: ASCO Abstracts 1-May-12 09:49 pm A search on the ASCO website showsIRWIN JAMES FRANKEL-5/2/2012
866Amgen was actually up on the day at new highs going back multiple years . . tuck-4/28/2012
865I would have expected a better response from EXEL today... 1:22AM Amgen receiveIan@SI-4/27/2012
864onclive.com Study Supports Combining c-MET Targeted Therapies With AngiogenesisIRWIN JAMES FRANKEL-4/16/2012
863SOUTH SAN FRANCISCO, Calif. (Business Wire) -- Exelixis, Inc. (NASDAQ:EXEL) annIan@SI-4/2/2012
862Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial CombiningDonShimoda-3/5/2012
861Cabozantinib (XL184) inhibits prostate tumor growth and bone lesion development DonShimoda-3/3/2012
860Dual Inhibition of MET and VEGF Signaling With Cabozantinib Blocks Tumor InvasivIRWIN JAMES FRANKEL-2/24/2012
859Exelixis Announces Pricing of $60.5 Million Public Offering of Common StockSOUTHtnsaf-2/10/2012
858XGEVA 12-1 vote against expanding use. Seems neutral with respect to cabo... Ian@SI-2/8/2012
857IJ, These results seem exceptional given the heavy pretreatments for the pts. Ian@SI-2/3/2012
856How far down the road? Ugh. Please, take me out behind the shed and put an end tscaram(o)uche-1/25/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News